down arrow

Entera Bio Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IL0011429839
USD
2.11
-0.11 (-4.95%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.072.25

52 Week

1.503.22
Valuation
Technical
Day's Volume

CASH

94.08 k

Shareholding (Mar 2025)

FII

0.61%

Held by 4 FIIs

DII

99.33%

Held by 1 DIIs

Promoter

0.00%

How big is Entera Bio Ltd.?

22-Jun-2025

As of Jun 18, Entera Bio Ltd. has a market capitalization of 95.00 million, with net sales of 0.22 million and a net profit of -10.10 million over the last four quarters. The company reported shareholder's funds of 8.08 million and total assets of 9.39 million as of Dec 24.

Market Cap: As of Jun 18, Entera Bio Ltd. has a market capitalization of 95.00 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Entera Bio Ltd. reported net sales of 0.22 million and a net profit of -10.10 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 8.08 million and total assets of 9.39 million.

Read More

What does Entera Bio Ltd. do?

22-Jun-2025

Entera Bio Ltd. is an Israel-based biotechnology company specializing in the oral delivery of large molecules and biologics. It has a market cap of $95 million and reported a net loss of $3 million in its most recent quarter.

Overview:<BR>Entera Bio Ltd. is an Israel-based biotechnology company focused on the oral delivery of large molecules and biologics within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 95.00 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.05 <BR>Return on Equity: -52.07% <BR>Price to Book: 4.90<BR><BR>Contact Details:<BR>Address: Kiryat Hadassah, Minrav Building, Fifth Floor JERUSALEM None : 9112002 <BR>Tel: 972 2 5327151 <BR>Website: http://www.enterabio.com/

Read More

Who are in the management team of Entera Bio Ltd.?

22-Jun-2025

As of March 2022, the management team of Entera Bio Ltd. includes Mr. Gerald Lieberman (Independent Chairman), Dr. Spiros Jamas (CEO), and directors Mr. Zeev Bronfeld, Mr. Sean Ellis, Mr. Yonatan Malca, Ms. Faith Charles, and Mr. Gerald Ostrov. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Entera Bio Ltd. includes the following individuals:<BR><BR>- Mr. Gerald Lieberman, Independent Chairman of the Board<BR>- Dr. Spiros Jamas, Chief Executive Officer and Director<BR>- Mr. Zeev Bronfeld, Director<BR>- Mr. Sean Ellis, Director<BR>- Mr. Yonatan Malca, Director<BR>- Ms. Faith Charles, Independent Director<BR>- Mr. Gerald Ostrov, Independent Director<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Read More

Is Entera Bio Ltd. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Entera Bio Ltd. shows a mildly bearish technical trend, with negative momentum indicators and underperformance compared to the S&P 500, reflecting a year-to-date return of -15.09%.

As of 9 September 2025, the technical trend for Entera Bio Ltd. has changed from sideways to mildly bearish. The weekly MACD is bearish, and the monthly MACD is mildly bearish, indicating a negative momentum. The daily moving averages also reflect a bearish stance. The Bollinger Bands show a bearish trend on the monthly timeframe. Additionally, the KST and Dow Theory are both mildly bearish on the weekly and monthly charts. The OBV indicates a mildly bearish trend weekly but is bullish monthly, suggesting some divergence in volume trends.<BR><BR>In terms of performance, Entera Bio has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -15.09% versus the S&P 500's 12.22%, and a one-year return of -14.29% compared to 17.14% for the index. Overall, the current technical stance is mildly bearish.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 91 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.08

stock-summary
Return on Equity

-61.44%

stock-summary
Price to Book

5.29

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.94%
0%
3.94%
6 Months
1.69%
0%
1.69%
1 Year
31.87%
0%
31.87%
2 Years
221.94%
0%
221.94%
3 Years
213.66%
0%
213.66%
4 Years
-33.02%
0%
-33.02%
5 Years
85.09%
0%
85.09%

Entera Bio Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Entera Bio Ltd. technically bullish or bearish?

As of 9 September 2025, the technical trend for Entera Bio Ltd. has changed from sideways to mildly bearish. The weekly MACD is bearish, and the monthly MACD is mildly bearish, indicating a negative momentum. The daily moving averages also reflect a bearish stance. The Bollinger Bands show a bearish trend on the monthly timeframe. Additionally, the KST and Dow Theory are both mildly bearish on the weekly and monthly charts. The OBV indicates a mildly bearish trend weekly but is bullish monthly, suggesting some divergence in volume trends. In terms of performance, Entera Bio has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -15.09% versus the S&P 500's 12.22%, and a one-year return of -14.29% compared to 17.14% for the index. Overall, the current technical stance is mildly bearish....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-1.87%
EBIT Growth (5y)
3.19%
EBIT to Interest (avg)
-10.87
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.05
Sales to Capital Employed (avg)
0.01
Tax Ratio
0.14%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
28.56%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.86
EV to EBIT
-7.31
EV to EBITDA
-7.34
EV to Capital Employed
-71.88
EV to Sales
73.68
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-52.07%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 1 Schemes (0.06%)

Foreign Institutions

Held by 4 Foreign Institutions (0.61%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -3.85% vs -8.33% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.70",
          "val2": "-2.60",
          "chgp": "-3.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.70",
          "val2": "-2.60",
          "chgp": "-3.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-61,023.80%",
          "chgp": "6,102.38%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -6.74% vs 32.06% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.50",
          "val2": "-8.90",
          "chgp": "-6.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.50",
          "val2": "-8.90",
          "chgp": "-6.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-52,955.80%",
          "val2": "0.00%",
          "chgp": "-5,295.58%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.70
-2.60
-3.85%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.70
-2.60
-3.85%
Operating Profit Margin (Excl OI)
0.00%
-61,023.80%
6,102.38%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -3.85% vs -8.33% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.20
0.00
Operating Profit (PBDIT) excl Other Income
-9.50
-8.90
-6.74%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-9.50
-8.90
-6.74%
Operating Profit Margin (Excl OI)
-52,955.80%
0.00%
-5,295.58%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -6.74% vs 32.06% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Entera Bio Ltd. stock-summary
stock-summary
Entera Bio Ltd.
Pharmaceuticals & Biotechnology
Entera Bio Ltd is an Israel-based product-focused biotechnology company that specializes in the oral delivery of large molecules and biologics. The Company conducts clinical trials on its proprietary technology, which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal (GI) tract. Entera Bio Ltd's technology addresses the major problems of oral drug delivery of large molecule active pharmaceutical ingredients (APIs). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract. The Company’s proprietary technologies act synergistically to transport and protect large molecules. The Company develops drugs for hypoparathyroidism, osteoporosis and bone healing.
Company Coordinates stock-summary
Company Details
Kiryat Hadassah, Minrav Building, Fifth Floor JERUSALEM None : 9112002
stock-summary
Tel: 972 2 5327151
stock-summary
http://www.enterabio.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."